Zobrazeno 1 - 10
of 376
pro vyhledávání: '"Michael F. Press"'
Autor:
Jie Ping, Guochong Jia, Qiuyin Cai, Xingyi Guo, Ran Tao, Christine Ambrosone, Dezheng Huo, Stefan Ambs, Mollie E. Barnard, Yu Chen, Montserrat Garcia-Closas, Jian Gu, Jennifer J. Hu, Esther M. John, Christopher I. Li, Katherine Nathanson, Barbara Nemesure, Olufunmilayo I. Olopade, Tuya Pal, Michael F. Press, Maureen Sanderson, Dale P. Sandler, Toshio Yoshimatsu, Prisca O. Adejumo, Thomas Ahearn, Abenaa M. Brewster, Anselm J. M. Hennis, Timothy Makumbi, Paul Ndom, Katie M. O’Brien, Andrew F. Olshan, Mojisola M. Oluwasanu, Sonya Reid, Song Yao, Ebonee N. Butler, Maosheng Huang, Atara Ntekim, Bingshan Li, Melissa A. Troester, Julie R. Palmer, Christopher A. Haiman, Jirong Long, Wei Zheng
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-8 (2024)
Abstract African-ancestry (AA) participants are underrepresented in genetics research. Here, we conducted a transcriptome-wide association study (TWAS) in AA female participants to identify putative breast cancer susceptibility genes. We built geneti
Externí odkaz:
https://doaj.org/article/b9834eb3a0344dc2a7b7b629b0f35afc
Autor:
Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet, Sara A. Hurvitz
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-14 (2023)
Abstract Background KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III breast cancer. We inve
Externí odkaz:
https://doaj.org/article/dc9caefbaf5f4cbcb3bf0e94081b2deb
Autor:
Sara Alsterlind Hurvitz, Nicholas P. McAndrew, Aditya Bardia, Michael F. Press, Mark Pegram, John P. Crown, Peter A. Fasching, Bent Ejlertsen, Eric H. Yang, John A. Glaspy, Dennis J. Slamon
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-25 (2021)
Abstract It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though the efficacy of anthracycline chemotherapy is not debatable, potentially life-threat
Externí odkaz:
https://doaj.org/article/aad7894979b94db08a790483d6338a18
Autor:
Babatunde Adedokun, Zhaohui Du, Guimin Gao, Thomas U. Ahearn, Kathryn L. Lunetta, Gary Zirpoli, Jonine Figueroa, Esther M. John, Leslie Bernstein, Wei Zheng, Jennifer J. Hu, Regina G. Ziegler, Sarah Nyante, Elisa V. Bandera, Sue A. Ingles, Michael F. Press, Sandra L. Deming-Halverson, Jorge L. Rodriguez-Gil, Song Yao, Temidayo O. Ogundiran, Oladosu Ojengbede, William Blot, Melissa A. Troester, Katherine L. Nathanson, Anselm Hennis, Barbara Nemesure, Stefan Ambs, Peter N. Fiorica, Lara E. Sucheston-Campbell, Jeannette T. Bensen, Lawrence H. Kushi, Gabriela Torres-Mejia, Donglei Hu, Laura Fejerman, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Douglas F. Easton, Kyriaki Michailidou, Paul D. P. Pharoah, Qin Wang, Dale P. Sandler, Jack A. Taylor, Katie M. O’Brien, Cari M. Kitahara, Adeyinka G. Falusi, Chinedum Babalola, Joel Yarney, Baffour Awuah, Beatrice Addai-Wiafe, The GBHS Study Team, Stephen J. Chanock, Andrew F. Olshan, Christine B. Ambrosone, David V. Conti, Elad Ziv, Olufunmilayo I. Olopade, Montserrat Garcia-Closas, Julie R. Palmer, Christopher A. Haiman, Dezheng Huo
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
GWAS have enhanced our understanding for the genetic basis of breast cancer, but the majority of them were performed for European ancestry populations. Here, the authors use a cross-ancestry approach and report seven new variants associated with brea
Externí odkaz:
https://doaj.org/article/6f0e5304a68d47149e5deb98e9b77d0a
Autor:
Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the patho
Externí odkaz:
https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55
Autor:
Nikhil Naik, Ali Madani, Andre Esteva, Nitish Shirish Keskar, Michael F. Press, Daniel Ruderman, David B. Agus, Richard Socher
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-8 (2020)
Determination of estrogen receptor status (ERS) in breast cancer tissue requires immunohistochemistry, which is sensitive to the vagaries of sample processing and the subjectivity of pathologists. Here the authors present a deep learning model that d
Externí odkaz:
https://doaj.org/article/169f3fde02b44f04a44160ad8fb94419
Autor:
Deborah L. Toppmeyer, Michael F. Press
Publikováno v:
Cancer Medicine, Vol 9, Iss 18, Pp 6463-6472 (2020)
Abstract Breast cancer is the most common cancer in women, and approximately 71% of carcinomas are hormone receptor‐positive (HR+) and human epidermal growth factor receptor 2‐not‐amplified (HER2‐negative). Pathogenesis of breast cancer is as
Externí odkaz:
https://doaj.org/article/16a6919863d64b7fbbbce9bf6bc5820c
Autor:
Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristin A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward S. Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette M. Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael F. Press, John David Carpten, Stephen J. Chanock, Jayesh Mehta, Graham A. Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 181-190 (2020)
Abstract: Persons of African ancestry (AA) have a twofold higher risk for multiple myeloma (MM) compared with persons of European ancestry (EA). Genome-wide association studies (GWASs) support a genetic contribution to MM etiology in individuals of E
Externí odkaz:
https://doaj.org/article/ba385add61f344c2bf8f3e2fb7c2bb2e
Autor:
Evan N. Cohen, Gitanjali Jayachandran, Richard G. Moore, Massimo Cristofanilli, Julie E. Lang, Joseph D. Khoury, Michael F. Press, Kyu Kwang Kim, Negar Khazan, Qiang Zhang, Youbin Zhang, Pushpinder Kaur, Roberta Guzman, Michael C. Miller, James M. Reuben, Naoto T. Ueno
Publikováno v:
Cancers, Vol 14, Iss 21, p 5238 (2022)
Circulating tumor cells (CTCs) captured from the blood of cancer patients may serve as a surrogate source of tumor material that can be obtained via a venipuncture (also known as a liquid biopsy) and used to better understand tumor characteristics. H
Externí odkaz:
https://doaj.org/article/2a9a1f523e2547b0a01ac0f0a024312a
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
Autor:
Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogene
Externí odkaz:
https://doaj.org/article/3b5c30a996d54c2086cfff5a285a1014